NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading CDXS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. CDXS operates in a challenging environment, marked by high risk and loss-making status, but recent financial performance has been strong, indicating potential for future growth.
The market currently prices CDXS as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully anticipate the company's ability to achieve its revenue guidance or improve its operating income.
Management is focused on achieving its 2026 revenue guidance of $72 million to $76 million, which appears on track based on recent growth. However, operating income remains negative, and cash flow from operations has shown volatility, indicating mixed results in fundamentals.
The long-term thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. If these companies continue to perform well, it could support CDXS's growth, but any negative shifts in their performance could pose risks.
Over the next 1 to 3 years, CDXS's prospects depend on both its execution and broader sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This report will provide updates on revenue, income, and cash flow. It is a key event.
Confirms one read:The earnings report shows revenue growth. It also shows better operating income.
Confirms the other:Earnings report shows declining revenue and worsening cash flow.
Why it matters: Confirming revenue guidance is key to maintaining investor confidence. A miss could signal deeper issues.
Confirms:Q2 revenue reported within the range of $18 million to $20 million.
Disproves:Q2 revenue reported below $18 million.
Why it matters: Improving operating income is key to showing better financial health. It signals progress.
Confirms:Operating income reported at less than -$5M.
Disproves:Operating income remains worse than -$8M.
Why it matters: Improving operating income is crucial for Codexis to show it can manage costs better. It impacts overall financial health.
Confirms:Operating income improves to less than -$8M in Q2.
Disproves:Operating income worsens to more than -$8M in Q2.
Why it matters: If revenue growth picks up, it could indicate a positive shift in the healthcare sector. This would benefit Codexis.
Confirms:Healthcare sector revenue growth is speeding up to nearly 10% each year.
Disproves:Healthcare sector revenue growth is slowing down to below 10% each year.
Why it matters: Better cash flow from operations means the company is managing costs well.
Confirms:Cash flow from operations reported at less than -$10M.
Disproves:Cash flow from operations remains worse than -$13M.
Why it matters: New leaders can change company plans and how well it performs.
Confirms one read:A new director or leadership plan has been announced.
Confirms the other:No new updates or changes in leadership have been announced.
Why it matters: Positive cash flow from operations is important for Codexis. It shows how well the company runs.
Confirms:Cash flow from operations turns positive in Q2.
Disproves:Cash flow from operations remains negative, worse than -$10M in Q2.
Why it matters: New partnerships could improve Codexis' market position and revenue. Delays may show challenges.
Confirms:Announcement of a new strategic partnership by the end of 2026.
Disproves:No new partnerships announced by the end of 2026.
